PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC L...

por Jurczak, W., Dartigeas, C., Coscia, M., Ganly, P., Al-Jazayrly, G., Wang, C., Bao, K., Leow, C. C., Shahda, S., Zinzani, P. L.
Publicado 2022

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

por Gagez, A-L, Tuaillon, E, Cezar, R, Dartigeas, C, Mahé, B, Letestu, R, Maisonneuve, H, Gouilleux-Gruart, V, Bollore, K, Ferrant, E, Aurran, T, Feugier, P, Leprêtre, S, Cartron, G
Publicado 2016